← CATALYST PHARMACEUTICALS, INC.

Annual Trend FY 2016 FY 2017 FY 2018 FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025
Cash flows from operating activities:
Adjustments to reconcile net income to net cash provided by operating activities:
Net Income From Continuing Operations — — — — — — $83.1m $71.4m $163.9m $214.3m
Net Income (Loss) Attributable to Parent ($18.1m) ($18.4m) ($34.0m) $31.9m $75.0m $39.5m $83.1m $71.4m $163.9m $214.3m
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest — — ($34.0m) $31.9m $75.0m $39.5m $83.1m $71.4m $163.9m $214.3m
Depreciation $43k $46k $38k $54k $92k $192k $141k $316k $397k $375k
Amortization of Intangible Assets — — — — — $0 $1.1m $32.6m $37.4m $37.5m
Amortization Cash Flow — — — — — — $1.1m $32.6m $37.4m $37.5m
Amortization Of Intangibles — — — — — — $1.1m $32.6m $37.4m $37.5m
Depreciation Amortization Depletion — — — — — — $1.2m $32.9m $37.8m $37.9m
Deferred Income Tax Expense (Benefit) — — — $0 ($33.0m) $9.3m — — — ($6.8m)
Deferred taxes — — — — ($33.0m) $9.3m $4.9m ($17.8m) ($9.4m) ($6.8m)
Deferred Income Tax — — — — — — $4.9m ($17.8m) ($9.4m) ($6.8m)
Deferred Tax — — — — — — $4.9m ($17.8m) ($9.4m) ($6.8m)
Share-based Payment Arrangement, Noncash Expense $1.8m $2.4m $3.6m $3.8m $6.3m $6.1m $7.9m $14.2m $22.3m $24.8m
Payment, Tax Withholding, Share-based Payment Arrangement $11k — $4k $0 $56k $153k $230k $982k $668k $1.8m
Impairment of Intangible Assets, Finite-lived — — — — — — $0 $0 $0 $0
Asset Impairment Charge — — — — — — — $0 $0 $464k
Income Tax Expense (Benefit) $0 $0 $0 $1.5m ($33.1m) $13.2m $21.6m $23.1m $52.4m $69.2m
Other Nonoperating Income (Expense) $322k $454k $1.3m $1.6m $587k $282k $2.9m $7.7m $21.1m $25.7m
Operating lease liability — — — ($277k) ($919k) $864k ($307k) ($338k) ($369k) ($401k)
Changes in operating assets and liabilities:
Additional Financial Items
Increase (Decrease) in Accounts Receivable — — — $10.5m ($4.5m) $632k $3.8m $43.1m $12.0m $61.0m
Increase (Decrease) in Inventories — — $56k $1.9m $2.7m $3.2m ($1.1m) $4.7m $3.9m $18.1m
Increase (Decrease) in Accounts Payable ($861k) $1.0m $392k $1.8m $139k ($1.5m) $1.2m $10.8m $1.8m ($5.4m)
Proceeds from Stock Options Exercised $80k $368k $298k $1.1m $758k $4.1m $9.6m $2.8m $13.5m $14.7m
Debt Securities, Available-for-sale, Realized Gain (Loss) — — — — — $0 $762k $0 $0 $0
Equity Securities, FV-NI, Gain (Loss) — — — — — — — $3.0m $5.1m $972k
Equity Securities, FV-NI, Unrealized Gain (Loss) — — — — — — — $3.0m $5.1m $972k
General and Administrative Expense $7.9m $7.3m $15.9m — — — — — $59.0m $63.1m
Operating Expenses $19.3m $18.7m $35.8m — — — — — $190.4m $206.5m
Stock-based compensation $1.8m $2.4m $3.6m $3.8m $6.3m $6.1m $7.9m $14.2m $22.3m $24.8m
Accretion of discount — — — — — ($5k) $17k $1.3m ($835k) ($350k)
Reduction in the carrying amount of right-of-use asset — — — $243k $793k $292k $247k $262k $278k $295k
Realized loss on sale of available-for-sale securities — — — — — — $762k $0 $0 —
Acquired research and development inventory expensed from asset acquisition — — — — — — $4.1m $0 $0 —
Acquired inventory samples expensed from asset acquisition — — — — — — $0 $130k $0 $0
Acquired in-process research and development — — — — — — $0 $81.5m $0 $0
Change in fair value of equity securities — — — — — $0 $0 ($3.0m) ($5.1m) ($972k)
Inventory reserve and write-offs — — — — — — — $0 $0 $464k
Accounts receivable, net — — — ($10.5m) $4.5m ($632k) ($3.8m) ($43.1m) ($12.0m) ($61.0m)
Inventory, net — — ($56k) ($1.9m) ($2.7m) ($3.2m) $1.1m ($4.7m) ($3.9m) ($18.1m)
Prepaid expenses and other current assets $457k ($126k) ($476k) ($2.7m) ($4.0m) $4.0m ($807k) ($5.8m) ($8.5m) ($177k)
Accounts payable ($861k) $1.0m $392k $1.8m $139k ($1.5m) $1.2m $10.8m $1.8m ($5.4m)
Accrued expenses and other liabilities ($480k) $1.1m $4.9m $12.5m ($1.2m) $5.5m $16.4m $5.8m $53.8m $24.2m
Proceeds from sale of available-for-sale securities — — — — $5.0m — $19.2m $0 $0 —
Payments in connection with asset acquisitions — — — — — — ($10.0m) ($198.3m) $0 $0
Acquisition of in-process research and development — — — — — — $0 ($81.5m) $0 $0
Purchase of equity securities — — — — — — $0 ($13.5m) $0 $0
Payment of employee withholding tax related to stock-based compensation ($11k) — ($4k) $0 ($56k) ($153k) ($230k) ($982k) ($668k) ($1.8m)
Proceeds from exercise of stock options $80k $368k $298k $1.1m $758k $4.1m $9.6m $2.8m $13.5m $14.7m
Payment of liabilities arising from asset acquisition — — — — — — ($738k) ($12.7m) ($12.9m) ($4.6m)
Liabilities arising from asset acquisition — — — — — — $27.7m $1.9m $0 $0
Accrued milestone payment classified as license and acquired intangibles, net — — — — — — — $0 $0 $12.5m
Beginning Cash Position — — — — — — $171.4m $298.4m $137.6m $517.6m
Cash Flow From Continuing Financing Activities — — — — — — $1.7m ($10.9m) $140.7m ($17.0m)
Cash Flow From Continuing Investing Activities — — — — — — $9.2m ($293.5m) ($556k) ($58k)
Change In Account Payable — — — — — — $1.2m $10.8m $1.8m ($5.4m)
Change In Accrued Expense — — — — — — $16.4m $5.8m $53.8m $24.2m
Change In Inventory — — — — — — $1.1m ($4.7m) ($3.9m) ($18.1m)
Change In Other Current Liabilities — — — — — — ($307k) ($338k) ($369k) ($401k)
Change In Payable — — — — — — $1.2m $10.8m $1.8m ($5.4m)
Change In Payables And Accrued Expense — — — — — — $17.6m $16.6m $55.6m $18.8m
Change In Prepaid Assets — — — — — — ($807k) ($5.8m) ($8.5m) ($177k)
Change In Receivables — — — — — — ($3.8m) ($43.1m) ($12.0m) ($61.0m)
Change In Working Capital — — — — — — $13.7m ($37.3m) $30.9m ($60.9m)
Changes In Account Receivables — — — — — — ($3.8m) ($43.1m) ($12.0m) ($61.0m)
Changes In Cash — — — — — — $127.0m ($160.8m) $379.9m $191.6m
End Cash Position — — — — — — $298.4m $137.6m $517.6m $709.2m
Financing Cash Flow — — — — — — $1.7m ($10.9m) $140.7m ($17.0m)
Free Cash Flow — — — — — — $116.0m $61.9m $239.3m $208.6m
Gain Loss On Sale Of PPE — — — — — $292k $247k $262k — —
Investing Cash Flow — — — — — — $9.2m ($293.5m) ($556k) ($58k)
Issuance Of Capital Stock — — — — — — $0 $0 $141.0m $0
Net Intangibles Purchase And Sale — — — — — — $0 ($81.5m) $0 $0
Net PPE Purchase And Sale — — — — — — ($29k) ($231k) ($556k) ($58k)
Operating Gains Losses — — — — — $292k $762k $262k — —
Other Non Cash Items — — — — — — $4.4m $83.2m ($557k) ($55k)
Proceeds From Stock Option Exercised — — — — — — $9.6m $2.8m $13.5m $14.7m
Purchase Of Intangibles — — — — — — $0 ($81.5m) $0 $0
Purchase Of PPE $96k $96k $92k $19k $11k $1.0m ($29k) ($231k) ($556k) ($58k)
Repurchase Of Capital Stock — — — — — — $0 $0 $0 ($25.3m)
Unrealized Gain Loss On Investment Securities — — — — — — $0 ($3.0m) ($5.1m) ($972k)
Net Cash Provided by (Used in) Operating Activities ($18.0m) ($13.7m) ($25.7m) $34.6m $45.0m $60.4m $116.0m $143.6m $239.8m $208.7m
Cash flows from investing activities:
Payments to Acquire Property, Plant, and Equipment $96k — $92k $19k $11k $1.0m $29k $231k $556k $58k
Payments to Acquire Investments — — $36.8m $34.7m $10.0m $10.0m — — — —
Net Investment Purchase And Sale — — — — — — $19.2m ($13.5m) $0 $0
Purchase Of Investment — — — — — — $0 ($13.5m) $0 $0
Sale Of Investment — — — — — $0 $19.2m $0 $0 —
Net Other Investing Changes — — — — — — ($10.0m) ($198.3m) — —
Net Cash Provided by (Used in) Investing Activities $3.6m ($4k) ($15.5m) $37.2m ($5.0m) ($11.0m) $9.2m ($293.5m) ($556k) ($58k)
Cash flows from financing activities:
Proceeds from Issuance of Common Stock — — — — — — — $0 $141.0m $0
Payment of fees in connection with issuance of common stock — — — — — — — $0 ($296k) $0
Common Stock Issuance — — — — — — $0 $0 $141.0m $0
Net Common Stock Issuance — — — — — — $0 $0 $141.0m ($25.3m)
Payments for Repurchase of Common Stock — — — — — $12.1m $6.9m $0 $0 $25.3m
Repurchase of common stock — — — — — ($12.1m) ($6.9m) $0 $0 ($25.3m)
Common Stock Payments — — — — — — $0 $0 $0 ($25.3m)
Dividends Payable, Current — — — $2 — — — — — —
Net Other Financing Charges — — — — — — ($7.9m) ($13.6m) ($13.8m) ($6.4m)
Net Cash Provided by (Used in) Financing Activities $69k $57.4m $293k $1.1m $702k ($8.1m) $1.7m ($10.9m) $140.7m ($17.0m)
Net increase (decrease) in cash and cash equivalents ($14.3m) $43.6m ($40.9m) $73.0m $40.7m $41.2m $127.0m ($160.8m) $379.9m $191.6m
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents — — — — — — $298.4m $137.6m $517.6m $709.2m
Cash and cash equivalents – beginning of period — — $57.5m $16.6m $89.5m $130.2m $298.4m $137.6m $517.6m $709.2m
Supplemental disclosure of cash flow information:
Change In Cash Supplemental As Reported — — — — — — $127.0m ($160.8m) $379.9m $191.6m
Interest Paid, Excluding Capitalized Interest, Operating Activities — — — — — — $0 $705k $1.4m $466k
Cash paid for income taxes — — — — $2.8m $3.0m $7.7m $50.5m $68.5m $72.0m

Data sourced from SEC EDGAR 10-K filings via EdgarTools. Amounts are shown in USD as reported in each fiscal year filing.